Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Potent new cholesterol biosynthesis inhibitors reported by Novartis

June 2, 1998

Theratechnologies' GRF analogues receive patent coverage

June 2, 1998

SR-146131, the most potent CCK-A receptor agonist reported to date

June 2, 1998

Novartis and Trega sign agreement for obesity and diabetes research

June 1, 1998

Compounds for bone diseases, neuropathy discovered at Takeda

June 1, 1998

AxyS Pharmaceuticals and Glaxo Wellcome discontinue diabetes/obesity collaboration

May 27, 1998

New beta3-adrenoceptor agonists discovered by SmithKline Beecham

May 27, 1998

The role of HMG-CoA reductase inhibitors in organ transplantation

May 27, 1998

Bio-Technology General and Serono announce copromotion agreement

May 26, 1998

Takeda establishes independent U.S. company, begins partnership with Lilly

May 26, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...